Get the Stockscreener App
7.46
2.47%
0.18
Pre-market:
7.44
-0.02
-0.27%
Organon Co stock is traded at $7.46, with a volume of 3.68M.
It is up +2.47% in the last 24 hours and down -14.84% over the past month.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$7.28
Open:
$7.31
24h Volume:
3.68M
Relative Volume:
0.68
Market Cap:
$1.94B
Revenue:
$6.28B
Net Income/Loss:
$700.00M
P/E Ratio:
2.771
EPS:
2.6922
Net Cash Flow:
$537.00M
1W Performance:
-2.99%
1M Performance:
-14.84%
6M Performance:
-19.61%
1Y Performance:
-51.81%
1-Day Range:
$7.25
$7.5489
1-Week Range:
$6.50
$7.58
52-Week Range:
$6.18
$16.18
Organon Co Stock (OGN) Company Profile
Name
Organon Co
Sector
Industry
Phone
551-430-6000
Address
30 HUDSON STREET, JERSEY CITY
Compare OGN vs LLY, JNJ, ABBV, AZN, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
7.46 | 1.89B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
1,020.56 | 977.37B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
244.99 | 586.40B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
228.72 | 411.55B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
208.67 | 324.75B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
165.38 | 317.08B | 54.72B | 14.02B | 15.32B | 7.1855 |
Organon Co Stock (OGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Oct-27-25 | Downgrade | Piper Sandler | Overweight → Underweight |
| May-02-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-06-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-03-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-21-23 | Initiated | Barclays | Overweight |
| Mar-16-23 | Initiated | Raymond James | Outperform |
| Oct-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-06-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-05-22 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-07-21 | Initiated | Piper Sandler | Neutral |
| Sep-01-21 | Initiated | BofA Securities | Buy |
| Jul-22-21 | Initiated | Citigroup | Buy |
| Jun-15-21 | Initiated | JP Morgan | Neutral |
| Jun-11-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-10-21 | Initiated | Evercore ISI | Outperform |
View All
Organon Co Stock (OGN) Latest News
5 Revealing Analyst Questions From Organon’s Q4 Earnings Call - Yahoo Finance UK
Organon & Co. (OGN) Stock Analysis: Evaluating a Potential 24.69% Upside in the Healthcare Sector - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Trading Systems Reacting to (OGN) Volatility - Stock Traders Daily
Organon (OGN) Is Down 10.0% After Earnings Miss And Cautious 2026 OutlookHas The Bull Case Changed? - simplywall.st
Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know - Finviz
BofA Securities Maintains Organon & Co(OGN.US) With Sell Rating - 富途牛牛
Organon (OGN) Is Down 12.8% After Earnings Miss And Flat 2026 Outlook Has The Bull Case Changed? - Yahoo Finance
OGN Q4 Deep Dive: Margin Compression and U.S. Headwinds Shape 2026 Outlook - Finviz
Organon & Co. Plans Quarterly Dividend of $0.02 (NYSE:OGN) - MarketBeat
Organon & Co. (NYSE:OGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Assessing Organon (OGN) Valuation After Earnings Miss And Flat 2026 Revenue Guidance - Yahoo Finance
LSV Asset Management Has $83.67 Million Holdings in Organon & Co. $OGN - MarketBeat
Organon Co earnings missed by $0.13, revenue fell short of estimates - Investing.com South Africa
Organon Reshapes Women’s Health Focus With Nexplanon Shift And Jada Sale - Yahoo Finance
Organon Q4 2025 slides: Revenue declines accelerate, stock tumbles on earnings miss By Investing.com - Investing.com South Africa
Organon Q4 2025 slides: Revenue declines accelerate, stock tumbles on earnings miss - Investing.com Canada
Organon & Co. Q4 Earnings Call Highlights - MarketBeat
Organon (NYSE:OGN) Reports Q4 CY2025 In Line With Expectations - The Globe and Mail
Organon & Co To Go Ex-Dividend On February 23rd, 2026 With 0.02 USD Dividend Per Share - 富途牛牛
Organon Earnings Call Balances Stability With Rising Risks - TipRanks
Organon Q3 Net Margin Squeeze Challenges Bullish Earnings Growth Narratives - simplywall.st
Organon & Co. Q4 2025 Earnings Call Summary - Yahoo Finance
Organon Shares Slide on Quarterly Loss and Cautious Outlook - AD HOC NEWS
Organon (OGN) Q4 2025 Earnings Call Transcript - The Globe and Mail
Organon & Co. (NYSE:OGN) Issues Earnings Results - MarketBeat
Organon: Overview of Fourth Quarter Financial Results - Bitget
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Investors to Inquire about Securities Investigation - ACCESS Newswire
Organon Q4 Earnings ReviewPoor Results Trigger Predictable Sell-Off (NYSE:OGN) - Seeking Alpha
Organon sees FY26 revenue $6.2B, consensus $6.11B - TipRanks
Organon outlines flat $6.2B revenue and $1.9B EBITDA targets for 2026 as cost controls and portfolio shifts take center stage - MSN
Organon reports Q4 adjusted EPS 63c, consensus 73c - TipRanks
Organon Shares Fall After 4Q Earnings Miss Expectations - 富途牛牛
Organon & Co. (NYSE:OGN) Shares Gap Down Following Weak Earnings - MarketBeat
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
OGN: 2025 results show stable revenue and EBITDA, with 2026 guidance flat amid margin and policy headwinds - TradingView
Organon Co earnings missed by $0.13, revenue fell short of estimates By Investing.com - Investing.com Canada
Earnings call transcript: Organon Q4 2025 reveals EPS miss, stock drops 10.8% - Investing.com
Organon (OGN) Misses Q4 Earnings and Revenue Estimates - Yahoo Finance
Organon falls as women’s health unit drives Q4 miss (OGN:NYSE) - Seeking Alpha
Organon: Q4 Earnings Snapshot - kare11.com
Organon Q4 Adjusted Earnings, Revenue Fall; 2026 Revenue Outlook Issued - 富途牛牛
Earnings snapshot: Organon & Co. misses bottom-line estimates; initiates FY26 outlook - MSN
Organon & Co (NYSE:OGN) Shares Drop on Q4 Earnings Miss and Flat 2026 Outlook - ChartMill
(OGN) Organon Expects 2026 Revenue About $6.22B, vs. FactSet Est of $6.11B - marketscreener.com
Earnings Flash (OGN) Organon Posts Q4 Revenue $1.51B, vs. FactSet Est of $1.54B - marketscreener.com
Earnings Flash (OGN) Organon Posts Q4 Adjusted EPS $0.63, vs. FactSet Est of $0.73 - marketscreener.com
Organon shares fall over 5% as Q4 earnings miss expectations By Investing.com - Investing.com South Africa
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025 - Business Wire
Organon Co Stock (OGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
1.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):